Pulmonology

Aluna and ModuleMD Partner to Bring 24/7 Remote Patient Monitoring to Practices and Respiratory Patients

Retrieved on: 
Monday, February 6, 2023
RPM, Allergy, Workflow, Patient, Cystic fibrosis, Allergist, Pulmonology, RCM, Asthma, EHR, Partnership, SAN, ONC, Practice management, Nursing, Aluna

SAN FRANCISCO, Feb. 6, 2023 /PRNewswire/ -- Today Aluna, an award-winning connected care platform and at-home spirometer, announced a partnership with ModuleMD, ONC Certified EHR, leading practice management and EHR SaaS solution for allergists and pulmonologists, to improve patient and provider access to the latest technology in lung health. Patients with asthma and cystic fibrosis will now be able to seamlessly share their daily fluctuations in lung health with their doctor, enabling better outcomes and fewer attacks through earlier and more frequent interventions.

Key Points: 
  • This collaboration will facilitate seamless sharing between providers, payers, and patients throughout the Aluna RPM care management platform with all the details integrated into the providers' workflow in ModuleMD.
  • "Close monitoring of asthma and other lung conditions is correlated with better patient outcomes," said Charvi Shetty, Founder and CEO of Aluna.
  • Through this integration with Aluna, medical practices now have a seamless RPM experience to deliver comprehensive care to patients."
  • Learn more about how practices can benefit from the Aluna and ModuleMD technology and service offerings.

What Are The Major Trend-Based Strategies That Players In The USA Pulmonologists Market Are Focusing On To Improve Treatment?

Retrieved on: 
Tuesday, January 24, 2023
Software, Diagnosis, Education, Endoscopy, Telehealth, Pulmonology, Respiratory system, Prevalence, Robotics, Patient, Tissue, Medical device, Hospital, Mercy Health

LONDON, Jan. 24, 2023 /PRNewswire/ -- As per The Business Research Company's pulmonologist market report, the increase in prevalence of lung disorders and the growing size of the geriatric population has compelled major players in the pulmonologist market to adopt advanced technologies to aid better treatment. Robotic Bronchoscopy is one such advanced diagnostic technology that pulmonologists are increasingly relying on for early and accurate detection of abnormal tissues in the lungs.

Key Points: 
  • Robotic Bronchoscopy is one such advanced diagnostic technology that pulmonologists are increasingly relying on for early and accurate detection of abnormal tissues in the lungs.
  • The USA pulmonologist market size is expected to grow from $2.1 billion in 2023 to $2.6 billion at a compound annual growth rate (CAGR) of 7.6%.
  • The pulmonologist market is then expected to grow to $3.8 billion in 2031 at a compound annual growth rate (CAGR) of 7.5%.
  • Because of the pulmonologist market's consistent growth potential, several market players are implementing various technological advancements as well as offering home healthcare services to remain competitive in the pulmonologist market.

What Are The Major Trend-Based Strategies That Players In The USA Pulmonologists Market Are Focusing On To Improve Treatment?

Retrieved on: 
Tuesday, January 24, 2023
Software, Diagnosis, Education, Endoscopy, Telehealth, Pulmonology, Respiratory system, Prevalence, Robotics, Patient, Tissue, Medical device, Hospital, Mercy Health

LONDON, Jan. 24, 2023 /PRNewswire/ -- As per The Business Research Company's pulmonologist market report, the increase in prevalence of lung disorders and the growing size of the geriatric population has compelled major players in the pulmonologist market to adopt advanced technologies to aid better treatment. Robotic Bronchoscopy is one such advanced diagnostic technology that pulmonologists are increasingly relying on for early and accurate detection of abnormal tissues in the lungs.

Key Points: 
  • Robotic Bronchoscopy is one such advanced diagnostic technology that pulmonologists are increasingly relying on for early and accurate detection of abnormal tissues in the lungs.
  • The USA pulmonologist market size is expected to grow from $2.1 billion in 2023 to $2.6 billion at a compound annual growth rate (CAGR) of 7.6%.
  • The pulmonologist market is then expected to grow to $3.8 billion in 2031 at a compound annual growth rate (CAGR) of 7.5%.
  • Because of the pulmonologist market's consistent growth potential, several market players are implementing various technological advancements as well as offering home healthcare services to remain competitive in the pulmonologist market.

4D Molecular Therapeutics Announces Updates on Clinical Pipeline and Additional Preclinical Programs

Retrieved on: 
Monday, January 9, 2023
IND, Disease, Partner (business rank), Echocardiography, PRISM, Clinical trial, Heart, Dialysis, A101, MD, GA, M.A, Degenerative disease, CF, Initiation, University of Nevada, Reno, Biopsy, Interim, NIH, QOL, University, IHC, Cystic fibrosis, Kidney, AMD, Toxic leukoencephalopathy, Intravitreal administration, RNA, Drug discovery, MRI, Choroideremia, Real-time, GMP, Stanford University School of Medicine, Development, Ahus, Fabry disease, Geographic atrophy, FDA, Retinitis pigmentosa, KCCQ, Addition, Atypical hemolytic uremic syndrome, Fabry, Principal, Ophthalmology, VG, Pulmonology, Enzyme replacement therapy, CFTR, DME, Clinical research, Safety, Diabetic retinopathy, ISH, Modulation, Pharmaceutical industry, Vaccine, 3D printing, Medical imaging, Patient

The doses to be evaluated in DME are expected to be similar to those used in the 4D-150 wet AMD clinical trial.

Key Points: 
  • The doses to be evaluated in DME are expected to be similar to those used in the 4D-150 wet AMD clinical trial.
  • It is estimated that there are over one million individuals with GA in the United States according to published data.
  • In addition, I’m excited by the potential of 4D-175, the new preclinical product candidate utilizing the same R100 vector.
  • Cardiac clinical endpoint data (MRI, echocardiography, cardiopulmonary exercise testing [CPET] and QOL assessment) from evaluations at baseline and 12 months after treatment were assessed.

Global Cord Blood and Tissue Banking Industry Report 2022: More than 70% of the Global Cord Blood Market is controlled by the World's 12 Largest Cord Blood Banking Operators - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023
Biotechnology, Baby, Maternity, Health, Consumer, Tooth fairy, Hypoxia (medical), Cerebral palsy, Infertility, Stemcell Technologies, Microsoft, Pulmonology, MNC, Autism, Bone marrow, Research, TNC, Stroke, ClinicalTrials.gov, Acquisition, Transplant, Regenerative medicine, Retail, Medical imaging, Pharmaceutical industry, Vaccine, Trapping, Firewood, Hospital, Dentistry

Today, more than 70% of the global cord blood market is controlled by the world's 12 largest cord blood banking operators.

Key Points: 
  • Today, more than 70% of the global cord blood market is controlled by the world's 12 largest cord blood banking operators.
  • Substantial cord blood industry consolidation has happened in recent years and investor appetite for cord blood banks has never been stronger.
  • Specifically, cord blood, cord tissue, placental tissue, and dental pulp have demonstrated intriguing therapeutic promise, causing storage services for these biomaterials to proliferate.
  • What are the prices for processing and storage of cord blood in private cord blood banks?

PERSOWN Inc. to launch SMASH-H, a near-real-time Sepsis Monitoring and Alerting System for Hospitals and Home powered by SAS advanced analytics

Retrieved on: 
Tuesday, January 10, 2023
SAS, Pulmonology, MD, Sepsis, Death, Hospital, Risk, Patient, Mortality, AI, Machine learning, Global Medical Device Nomenclature, Informatics, National Association Medical Staff Services, Incidence, Intelligence, Pharmaceutical industry, Medicine

ATLANTA, Jan. 10, 2023 /PRNewswire/ -- Medical information technology and diagnostics company PERSOWN, Inc. is addressing the global burden of sepsis with the launch of the open platform SMASH-H (Sepsis Monitoring and Alerting System for Hospitals and Homes), powered by healthcare analytics from SAS .

Key Points: 
  • ATLANTA, Jan. 10, 2023 /PRNewswire/ -- Medical information technology and diagnostics company PERSOWN, Inc. is addressing the global burden of sepsis with the launch of the open platform SMASH-H (Sepsis Monitoring and Alerting System for Hospitals and Homes), powered by healthcare analytics from SAS .
  • SMASH-H will provide hospitals access to a common set of predictive models designed to enhance existing IT platforms, monitoring tools and diagnostic products.
  • Sepsis has one of the highest mortality rates of any hospital condition, estimated at 15% to 30%.
  • PERSOWN seeks collaborative hospitals from around the world to launch the platform for clinical researchers and treatment protocol analytics.

FDA Approves Polarean’s XENOVIEW™ (xenon Xe 129 hyperpolarized) for use with MRI for the Evaluation of Lung Ventilation

Retrieved on: 
Wednesday, December 28, 2022
Xenon, Chronic lung disease, Software, Ageing, MRI, Cincinnati, Ventilation, Food, Lung, Pulmonology, Regulation of tobacco by the U.S. Food and Drug Administration, Research, Adolescence, Surgeon, NDA, VDP, Disease, Radiation, Patient, Classification, FDA, Northwest Hospital & Medical Center, Xe, Magnetic resonance imaging, AIM, Medical imaging, Medical device

XENOVIEW, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (“MRI”) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older.

Key Points: 
  • XENOVIEW, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (“MRI”) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older.
  • XENOVIEW expands the opportunity for pulmonary medicine to utilize the first and only inhaled MRI hyperpolarized contrast agent for novel visualization of lung ventilation without exposing patients to any ionizing radiation and its associated risks.
  • The dose of XENOVIEW, created through the Polarean HPX hyperpolarization system, is administered in a single 10-15 second breath hold MRI procedure.
  • More than 30 million Americans suffer from a chronic lung disease and there is a significant unmet need for non-invasive diagnostic technology.

Dr. Yuko Yamasaki Receives RSNA’s Cum Laude Award for Dynamic Digital Radiography Education Exhibit During Annual Meeting

Retrieved on: 
Wednesday, December 21, 2022
Education, DCR, Editorial, Motion, MD, Research, Anatomy, Pulmonology, Radiological Society of North America, CTEPH, Kyushu University, DDR, Latin honors, RSNA, Radiation, CT, Nuclear medicine, Correlation and dependence, Minolta, Senior, Doctor of Philosophy, Agent handling, Medical imaging, Radiology, Marketing

Dr. Yamasaki’s education exhibit, “Dynamic Chest Radiography for Pulmonary Vascular Diseases: Clinical Applications and Correlation with Other Imaging Modalities,” was one of 43 Cum Laude awards given to the 1,454 education exhibits presented at RSNA 2022, and one of only five X-ray-focused presentations to receive an award this year.

Key Points: 
  • Dr. Yamasaki’s education exhibit, “Dynamic Chest Radiography for Pulmonary Vascular Diseases: Clinical Applications and Correlation with Other Imaging Modalities,” was one of 43 Cum Laude awards given to the 1,454 education exhibits presented at RSNA 2022, and one of only five X-ray-focused presentations to receive an award this year.
  • DDR is an evolution in radiographic technology that provides a series of individual digital X-ray images acquired at high speed and low radiation dose.
  • Dr. Yamasaki’s education exhibit discussed the advantages of DCR (aka DDR) compared to other imaging modalities for lung perfusion and ventilation assessment.
  • “Konica Minolta congratulates Dr. Yamasaki for his excellent work and educational exhibit on the use of DDR for evaluating pulmonary diseases.

Pulmonary Drug Delivery Systems Market Report 2022: Featuring Abbott, Dr. Reddy's Laboratories, GlaxoSmithKline, Lupin and Pfizer - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 20, 2022
Pharmaceutical, Health, Medical Devices, GlaxoSmithKline, COPD, Death, Cystic fibrosis, Pfizer, Pulmonology, USD, Risk, Epidemiology, R, Chronic obstructive pulmonary disease, Acquisition, Growth, Developing country, World Health Organization, Administration, Dust, Lupinus, Laboratory, Degenerative disease, Asthma, Genetics, Prevalence, WHO, Phlegm, Pharmaceutical industry, Medical device

The "Pulmonary Drug Delivery Systems: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pulmonary Drug Delivery Systems: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • This report will provide a detailed look at the pulmonary drug delivery systems market, highlighting major pulmonary diseases with detailed epidemiology for major disease areas such as asthma, COPD and cystic fibrosis.
  • Pulmonary drug delivery is an alternative to oral drug delivery.
  • The market for pulmonary drug delivery systems is growing rapidly due to the rising prevalence of respiratory disorders such as asthma, COPD and other chronic illnesses.

Jahaira L. Serrano, MD is recognized by Continental Who's Who

Retrieved on: 
Friday, January 6, 2023
Mentorship, COPD, Medical degree, American College, Diagram, Lung, Physician, Internal medicine, COVID-19, NBPS, Histology, Respiratory system, Multimedia, University of Puerto Rico School of Dental Medicine, Suite, Mortality, Pulmonology, Ministry of Health (New South Wales), Patient, American College of Chest Physicians, Private practice, Pneumonia, Nose, DOS, University, Pharynx, National Board of Medical Examiners, Respiratory disease, Asthma, Chest infection, Degenerative disease, Service, Continental, Chronic obstructive pulmonary disease, University of Puerto Rico School of Medicine, Medical device, Surgeon, Incidence, MD, Science, Medicine, Biology

ARECIBO, Puerto Rico, Jan. 6, 2023 /PRNewswire/ -- Jahaira L. Serrano, MD, FACCP, is being recognized by Continental Who's Who as a Distinguished Healthcare Provider in the medical field and for her contributions at Serrano Pulmonary Services.

Key Points: 
  • ARECIBO, Puerto Rico, Jan. 6, 2023 /PRNewswire/ -- Jahaira L. Serrano, MD, FACCP, is being recognized by Continental Who's Who as a Distinguished Healthcare Provider in the medical field and for her contributions at Serrano Pulmonary Services.
  • Dr. Serrano completed an Internal Medicine residency in 2005 and Pulmonary Medicine Fellowship in 2007, both at the University of Puerto Rico University District Hospital.
  • Dr. Serrano treats patients at Serrano Pulmonary Services, located at 702 Ave San Luis, Suite 129 in Arecibo, Puerto Rico.
  • Dr. Serrano would like to dedicate this honor to her mother, Mrs. Maria Dominguez, and her mentors, Ruth Santos, MD, and Yohana de Jesús, MD.